Hospital
Uva Prince William Medical Center
Uva Prince William Medical Center was paid $10.85M by Medicaid between Jan 2018 and Dec 2024, across 140 billing codes. Its largest line is 99283, emergency room visit (moderate) — 22% of everything it billed.
33Billing provider infoUVA PRINCE WILLIAM MEDICAL CENTER
HAYMARKET, VA 20169
HAYMARKET, VA 20169
33aNPI1124369137assigned 03/15/2013
33bProvider typeGeneral Acute Care Hospital
28Total paid$10.85M
24GClaims225,192
24DCodes billed140
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Virginia
Rank by total paid#50 of 80
Median peer was paid$14.69M
This provider vs. median0.7×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official CODER, CHARLES controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 22,188 | $667K | |
| 2019 | 31,351 | $1.03M | |
| 2020 | 27,719 | $850K | |
| 2021 | 35,526 | $1.06M | |
| 2022 | 40,078 | $1.91M | |
| 2023 | 37,460 | $3.09M | |
| 2024incomplete | 30,870 | $2.24M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 22% | 10,690 | 9,576 | $2.40M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 21% | 9,274 | 8,157 | $2.28M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 13% | 4,828 | 4,258 | $1.41M |
| 96361 | Intravenous infusion, hydration; each additional hour | 8.6% | 4,198 | 3,555 | $936K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 6.8% | 2,577 | 2,328 | $741K |
| 70450 | Computed tomography, head or brain; without contrast material | 4.9% | 2,218 | 1,972 | $536K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 4.4% | 2,446 | 2,164 | $479K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | 3.1% | 3,044 | 2,859 | $342K |
| G0378 | Hospital observation service, per hour | 2.4% | 2,133 | 960 | $255K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | 1.6% | 1,020 | 895 | $178K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | 1.3% | 215 | 170 | $141K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.2% | 1,198 | 965 | $135K |
128 more codes
| 71275 | Computed tomographic angiography, chest, with contrast material | 1.2% | 364 | $127K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 1,596 | $95K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 603 | $78K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 237 | $77K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 195 | $65K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 1,140 | $56K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 1,008 | $53K |
| 41899 | Unlisted procedure, dentoalveolar structures | <1% | 44 | $48K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 2,110 | $46K |
| 80053 | Comprehensive metabolic panel | <1% | 11,405 | $40K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 2,100 | $39K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 547 | $31K |
| 76830 | Ultrasound, transvaginal | <1% | 235 | $26K |
| 76642 | <1% | 128 | $26K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 405 | $25K |
| J3490 | Unclassified drugs | <1% | 29,290 | $23K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 94 | $19K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 3,041 | $16K |
| 97161 | <1% | 159 | $11K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 4,596 | $9K |
| 71045 | Radiologic examination, chest; single view | <1% | 3,999 | $7K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 12,030 | $6K |
| 87420 | <1% | 301 | $6K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 7,923 | $6K |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 14 | $5K |
| 84484 | <1% | 4,168 | $5K | |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | <1% | 155 | $5K |
| J8597 | Antiemetic drug, oral, not otherwise specified | <1% | 964 | $4K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 172 | $4K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 14 | $4K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 941 | $4K |
| 85027 | <1% | 2,701 | $3K | |
| 93971 | <1% | 15 | $3K | |
| 76770 | <1% | 14 | $3K | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 29 | $3K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 1,651 | $3K |
| 76536 | <1% | 13 | $3K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 180 | $2K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 6,517 | $2K |
| 80299 | <1% | 436 | $2K | |
| 87040 | <1% | 322 | $2K | |
| 85379 | <1% | 506 | $2K | |
| 80143 | <1% | 254 | $2K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 117 | $2K |
| 77062 | <1% | 16 | $2K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 13 | $2K |
| 87631 | <1% | 128 | $2K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 5,561 | $1K |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 112 | $1K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 5,159 | $1K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 2,873 | $1K |
| 82962 | <1% | 1,193 | $1K | |
| 74018 | <1% | 57 | $1K | |
| 73630 | <1% | 115 | $1K | |
| 81001 | <1% | 2,738 | $987.32 | |
| 73030 | <1% | 40 | $973.34 | |
| 83735 | <1% | 3,599 | $968.25 | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 2,194 | $878.41 |
| 80179 | <1% | 283 | $871.65 | |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 117 | $855.48 |
| 77066 | Tomosynthesis, mammo | <1% | 17 | $768.02 |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 4,494 | $743.99 |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 284 | $691.30 |
| 85610 | <1% | 1,671 | $624.62 | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 14 | $573.29 |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 2,644 | $567.62 |
| 97165 | <1% | 14 | $551.30 | |
| 73610 | <1% | 66 | $521.38 | |
| 81003 | <1% | 2,710 | $508.62 | |
| 83690 | <1% | 3,631 | $467.21 | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 1,080 | $463.27 |
| 96376 | <1% | 1,817 | $443.50 | |
| 84703 | <1% | 2,219 | $440.19 | |
| 73564 | <1% | 33 | $426.31 | |
| 83880 | <1% | 276 | $417.86 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 2,473 | $411.88 |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 4,609 | $404.36 |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 2,536 | $360.07 |
| 81025 | <1% | 1,688 | $335.92 | |
| 36415 | Collection of venous blood by venipuncture | <1% | 169 | $332.49 |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 113 | $271.95 |
| 87430 | <1% | 772 | $240.20 | |
| J2274 | Injection, morphine sulfate, preservative-free for epidural or intrathecal use, 10 mg | <1% | 16 | $205.66 |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 18 | $205.31 |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 1,978 | $194.15 |
| 86901 | <1% | 404 | $191.12 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 2,386 | $188.05 |
| 83605 | <1% | 540 | $170.01 | |
| 84702 | <1% | 301 | $153.89 | |
| 87070 | <1% | 806 | $153.18 | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 12 | $143.51 |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 1,682 | $137.57 |
| 86900 | <1% | 203 | $135.65 | |
| 88342 | <1% | 103 | $115.73 | |
| 85730 | <1% | 259 | $102.88 | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 428 | $93.16 |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 12 | $70.98 |
| 73562 | <1% | 14 | $70.54 | |
| 87150 | <1% | 22 | $57.99 | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 881 | $49.63 |
| J2704 | Injection, propofol, 10 mg | <1% | 3,272 | $47.02 |
| 87186 | <1% | 331 | $46.76 | |
| 87081 | <1% | 229 | $35.39 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 568 | $33.33 |
| 82150 | <1% | 194 | $26.34 | |
| 85007 | <1% | 13 | $21.78 | |
| 86850 | <1% | 15 | $19.04 | |
| 87205 | <1% | 23 | $15.25 | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 495 | $14.89 |
| 82550 | <1% | 31 | $12.36 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 483 | $12.21 |
| A9270 | Non-covered item or service | <1% | 3,778 | $6.12 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 122 | $4.30 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 15 | $2.70 |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | <1% | 13 | $2.07 |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | 0% | 234 | $0.00 |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | 0% | 424 | $0.00 |
| C1751 | Catheter, infusion, inserted peripherally, centrally or midline (other than hemodialysis) | 0% | 142 | $0.00 |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | 0% | 86 | $0.00 |
| 88360 | 0% | 15 | $0.00 | |
| J1171 | Injection, hydromorphone, 0.1 mg | 0% | 18 | $0.00 |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | 0% | 14 | $0.00 |
| J1650 | Injection, enoxaparin sodium, 10 mg | 0% | 20 | $0.00 |
| J8499 | Prescription drug, oral, non chemotherapeutic, nos | 0% | 82 | $0.00 |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | 0% | 290 | $0.00 |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | 0% | 60 | $0.00 |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 0% | 13 | $0.00 |
| A9585 | Injection, gadobutrol, 0.1 ml | 0% | 45 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialCODER, CHARLES (CHIEF FINANCIAL OFFICER)
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.